PBA
CCCC icon

Paradigm Biocapital Advisors’s C4 Therapeutics CCCC Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-73,149
Closed -$552K – 29
2022
Q2 		$552K Sell
73,149
-426,347
-85% -$3.75M 0.11% 23
2022
Q1 		$12.1M Buy
499,496
+240,750
+93% +$5.85M 3.2% 15
2021
Q4 		$8.33M Buy
+258,746
New +$10.2M 2.38% 17

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Paradigm Biocapital Advisors's CCCC Position: Q3 2022 in Review

Paradigm Biocapital Advisors sold out of C4 Therapeutics (CCCC) in Q3 2022, closing a stake of 73,149 shares — an estimated $552K sold.

Paradigm Biocapital Advisors first reported a position in CCCC in Q4 2021 and held it in 3 quarters. The position peaked at $12.1M in Q1 2022. 114 funds tracked by Wall St. Rank hold CCCC as of Q3 2022.

  • Paradigm Biocapital Advisors reported no remaining C4 Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 73,149 C4 Therapeutics shares in Q3 2022, an estimated $552K.
  • Paradigm Biocapital Advisors first reported a position in C4 Therapeutics in Q4 2021 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's C4 Therapeutics position peaked at $12.1M in Q1 2022.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.